Company logo

APDN - Applied DNA Sciences, Inc.

NASDAQ -> Healthcare -> Diagnostics & Research
Stony Brook, United States
Type: Equity
APDN price evolution
APDN
(in millions $) 1 May 2024 31 Jan 2024 30 Oct 2023 30 Jul 2023
Current assets
Cash $4.11 $7.9 $11.51
Short term investments
Net receivables $0.45 $0.26 $0.68
Inventory $0.38 $0.33 $0.28
Total current assets $4.59 $8.13 $12.24
Long term investments
Property, plant & equipment $1.66 $2.08 $2.52
Goodwill & intangible assets $2.92 $2.7 $0.28
Total noncurrent assets $5.32 $5.53 $3.55
Total investments
Total assets $9.91 $13.65 $15.79
Current liabilities
Accounts payable $2.02 $2.27 $2.13
Deferred revenue $0.28 $0.27 $0.28
Short long term debt $0.51 $0.5 $0.49
Total current liabilities $2.59 $2.85 $2.89
Long term debt $0.61 $0.74 $0.87
Total noncurrent liabilities $3.2 $5.93 $5.7
Total debt $1.12 $1.24 $1.36
Total liabilities $5.78 $8.78 $8.6
Shareholders' equity
Retained earnings -$303.63 -$302.45 -$298.85
Other shareholder equity
Total shareholder equity $4.23 $4.95 $7.25
(in millions $) 31 Dec 2023 30 Oct 2022 31 Dec 2021 31 Dec 2020
Current assets
Cash $7.9 $15.31 $6.65 $7.88
Short term investments
Net receivables $0.26 $3.07 $2.8 $0.19
Inventory $0.33 $0.6 $1.37 $0.5
Total current assets $8.13 $19.94 $11.3 $9.08
Long term investments
Property, plant & equipment $2.08 $2.22 $3.02 $1.28
Goodwill & intangible assets $2.7 $0.89
Total noncurrent assets $5.53 $2.32 $3.12 $2.26
Total investments
Total assets $13.65 $22.27 $14.42 $11.34
Current liabilities
Accounts payable $2.27 $1.74 $2.99 $1.93
Deferred revenue $0.27 $0.56 $0.28 $0.51
Short long term debt $0.5 $1.83
Total current liabilities $2.85 $4.19 $3.27 $4.27
Long term debt $0.74 $0.52
Total noncurrent liabilities $5.93 $5.17 $0.03 $1.37
Total debt $1.24 $2.35
Total liabilities $8.78 $9.35 $3.3 $5.63
Shareholders' equity
Retained earnings -$302.45 -$292.5 -$284.12 -$269.84
Other shareholder equity -$0.01
Total shareholder equity $4.95 $12.91 $11.11 $5.72
(in millions $) 1 May 2024 31 Jan 2024 30 Oct 2023 30 Jul 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense
Net income
Net income
Income (for common shares)
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $13.37 $18.17 $9.03 $1.93
Cost of revenue $7.83 $13.12 $4.1 $0.72
Gross Profit $5.53 $5.05 $4.93 $1.21
Operating activities
Research & development $3.74 $3.93 $3.77 $3.32
Selling, general & administrative $12.75 $15.1 $12.61 $10.14
Total operating expenses $16.49 $19.02 $18.04 $13.75
Operating income -$10.95 -$13.97 -$13.11 -$12.53
Income from continuing operations
EBIT -$9.95 -$8.28 -$14.3 -$12.91
Income tax expense
Interest expense -$0.01 -$0.01 $0.12
Net income
Net income -$9.95 -$8.27 -$14.29 -$13.03
Income (for common shares) -$9.95 -$8.38 -$14.29 -$13.03
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$1.11 -$3.59 -$3.1 $0.59
Operating activities
Depreciation $0.3 $0.33 $0.35 $0.34
Business acquisitions & disposals -$0.92 -$0.14
Stock-based compensation $0.34 $0.34 $0.34 $0.26
Total cash flows from operations -$3.76 -$2.68 -$1.37 $0.21
Investing activities
Capital expenditures $0 -$0.02 -$0.05
Investments
Total cash flows from investing -$0.92 -$0.16 -$0.05
Financing activities
Dividends paid
Sale and purchase of stock $0.05
Net borrowings
Total cash flows from financing -$0.04
Effect of exchange rate
Change in cash and equivalents -$3.79 -$3.6 -$1.53 $0.16
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$9.95 -$8.27 -$14.29 -$13.03
Operating activities
Depreciation $1.36 $1.29 $0.84 $0.29
Business acquisitions & disposals -$1.06
Stock-based compensation $1.03 $2.52 $1.67 $1
Total cash flows from operations -$6.22 -$8.98 -$13.39 -$11.14
Investing activities
Capital expenditures -$0.03 -$0.49 -$2.55 -$1.06
Investments
Total cash flows from investing -$1.1 -$0.49 -$2.55 -$1.06
Financing activities
Dividends paid
Sale and purchase of stock $18.13 $16.37 $18.7
Net borrowings -$1.67 $0.74
Total cash flows from financing $18.13 $14.7 $19.43
Effect of exchange rate
Change in cash and equivalents -$7.31 $8.66 -$1.23 $7.23
News
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance 10 Feb 2024
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance 12 Dec 2023
Charles River (CRL) Announces Partnership With Related Sciences
Zacks via Yahoo Finance 15 Sep 2023
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q2 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance 16 May 2023
Consultant sees 'ton of promise' in Navidea Biopharmaceuticals as top exec steps down
The Business Journals 4 Apr 2023
Sorry, Technology Can’t Replace Your Supply Chain Due Diligence Yet
The National Law Review 24 Mar 2023
Natasha Irons (New Earth)
Fandom 18 Feb 2023
Startups Take On Illumina in Race for Cheaper DNA Sequencing
The Wall Street Journal 16 Feb 2023
Applied DNA gets up to $1.5M in tax breaks, agrees to hire 23
Newsday 14 Feb 2023
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance 12 Feb 2023
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding N/A
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 1.77
Net debt/EBITDA N/A
Current ratio N/A
Quick ratio N/A

Copyright Statfolio @ 2024

Social Accounts